Cellectis SA (NASDAQ:CLLS) Sees Significant Growth in Short Interest

Cellectis SA (NASDAQ:CLLS) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 202,800 shares, an increase of 60.1% from the August 30th total of 126,700 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 114,500 shares, the short-interest ratio is presently 1.8 days.

A number of equities analysts have recently commented on CLLS shares. BTIG Research started coverage on shares of Cellectis in a report on Friday, August 9th. They set a “buy” rating and a $37.00 price target on the stock. Zacks Investment Research upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, August 26th. BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a report on Saturday, August 17th. Goldman Sachs Group set a $20.00 price target on shares of Cellectis and gave the stock a “hold” rating in a report on Monday, August 12th. Finally, ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Cellectis presently has an average rating of “Hold” and an average target price of $31.67.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. A.R.T. Advisors LLC bought a new position in Cellectis during the second quarter worth $171,000. Point72 Asset Management L.P. raised its stake in Cellectis by 66.9% during the second quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock worth $2,223,000 after buying an additional 57,100 shares during the last quarter. Aperio Group LLC bought a new position in Cellectis during the second quarter worth $147,000. OneAscent Financial Services LLC bought a new position in Cellectis during the second quarter worth $257,000. Finally, ARK Investment Management LLC raised its stake in Cellectis by 18.1% during the second quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock worth $17,210,000 after buying an additional 169,110 shares during the last quarter. 31.65% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:CLLS traded down $0.02 during mid-day trading on Friday, reaching $9.84. 104,596 shares of the company’s stock were exchanged, compared to its average volume of 130,307. The firm has a market capitalization of $417.71 million, a price-to-earnings ratio of -5.10 and a beta of 1.74. The business’s fifty day moving average price is $11.49 and its 200-day moving average price is $15.43. The company has a debt-to-equity ratio of 0.11, a quick ratio of 8.46 and a current ratio of 8.47. Cellectis has a twelve month low of $9.50 and a twelve month high of $28.24.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The business had revenue of $2.93 million for the quarter, compared to analyst estimates of $3.45 million. Analysts predict that Cellectis will post -2.9 EPS for the current fiscal year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Recommended Story: Stop Order Uses For Individual Investors

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit